Eckert Siegfried, Freytag Siegfried B, Müller Alfons, Klebs Sven H G
Department of Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany.
Blood Press. 2013 Sep;22 Suppl 1:11-21. doi: 10.3109/08037051.2013.793891. Epub 2013 May 29.
In this study, the effectiveness of amlodipine/valsartan single-pill combination was assessed in hypertensive patients with diabetes, metabolic risk or overweight.
Data from 12,265 patients treated with amlodipine/valsartan from three studies were analyzed in a meta-analysis. These studies focused on (i) non-diabetic hypertensive patients suffering from abdominal obesity; (ii) hypertensive patients with at least one metabolic risk factor; and (iii) hypertensive patients with type 2 diabetes mellitus. The observation periods were 16 weeks for the first two and 24 weeks for the latter cohort.
At start of observation, the mean blood pressure was 162.3 mmHg (systolic) and 93.5 mmHg (diastolic). A total of 7.4% of patients were aged ≥ 80 years. At end of the observation, a normalized blood pressure was present in 38.8% of patients. No appreciable differences in blood pressure reduction were evident between the study groups. In both age subgroups (< 80 years and ≥ 80 years) blood pressure reduction was comparable. Tolerability was assessed by treating physicians as "very good" (69.3%) and "good" (27.3%).
In daily practice, treatment of hypertensive patients with additional risk factors with amlodipine/valsartan single-pill combinations is well tolerated and associated with effective reduction of blood pressure.
在本研究中，评估氨氯地平/缬沙坦单片复方制剂对伴有糖尿病、代谢风险或超重的高血压患者的有效性。
对三项研究中12265例接受氨氯地平/缬沙坦治疗的患者数据进行荟萃分析。这些研究聚焦于：（i）患有腹型肥胖的非糖尿病高血压患者；（ii）至少有一项代谢风险因素的高血压患者；以及（iii）2型糖尿病高血压患者。前两组的观察期为16周，后一组为24周。
观察开始时，平均血压为收缩压162.3 mmHg，舒张压93.5 mmHg。共有7.4%的患者年龄≥80岁。观察结束时，38.8%的患者血压恢复正常。各研究组之间在血压降低方面无明显差异。在两个年龄亚组（<80岁和≥80岁）中，血压降低情况相当。治疗医生将耐受性评估为“非常好”（69.3%）和“好”（27.3%）。
在日常实践中，使用氨氯地平/缬沙坦单片复方制剂治疗伴有其他风险因素的高血压患者耐受性良好，且能有效降低血压。
